| Trial ID: | L6584 |
| Source ID: | NCT00042471
|
| Associated Drug: |
Pramlintide Acetate
|
| Title: |
Evaluation of the Bioavailability of Pramlintide
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Pramlintide acetate
|
| Outcome Measures: |
Primary: Effect of varying needle length on bioavailability of Pramlintide, To determine the effect of various anatomical injection sites and varying needle lengths upon the absolute bioavailability of pramlintide when injected subcutaneously (SC) in non-obese and obese subjects with type 1 and type 2 diabetes mellitus using insulin., approximately 6days but not to exceed 14days | Secondary: Effect of varying needle length on safety and tolerability of Pramlintide, To assess the safety and tolerability of pramlintide when injected SC at various anatomical sites and with various needle lengths in non-obese and obese subjects with type 1 and type 2 diabetes mellitus using insulin, Approximately 6 days not to exceed 14days
|
| Sponsor/Collaborators: |
Sponsor: AstraZeneca
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
75
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2002-06
|
| Completion Date: |
2002-12
|
| Results First Posted: |
|
| Last Update Posted: |
2015-09-23
|
| Locations: |
Orlando Clinical Research Center, Orlando, Florida, United States|New Orleans Center for Clinical Research, New Orleans, Louisiana, United States|DaVita Clinical Research, Minneapolis, Minnesota, United States|CEDRA Clinical Research, LLC, Austin, Texas, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00042471
|
